Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review

作者全名："Wang, Qiang; Wang, Anrong; Li, Zhen; Sparrelid, Ernesto; Brismar, Torkel B. B."

作者地址："[Wang, Qiang; Brismar, Torkel B. B.] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Med Imaging & Technol, Stockholm, Sweden; [Wang, Qiang; Brismar, Torkel B. B.] Karolinska Univ Hosp Huddinge, Dept Radiol, Stockholm, Sweden; [Wang, Anrong] Chongqing Med Univ, Dept Vasc Surg, Affiliated Hosp 1, Chongqing, Peoples R China; [Wang, Anrong] Peoples Hosp Dianjiang Cty, Dept Intervent Therapy, Chongqing, Peoples R China; [Li, Zhen] Peoples Hosp Dianjiang Cty, Dept Hepatobiliary Surg, Chongqing, Peoples R China; [Sparrelid, Ernesto] Karolinska Univ Hosp, Stockholm, Sweden"

通信作者："Li, Z (通讯作者)，Peoples Hosp Dianjiang Cty, Dept Hepatobiliary Surg, Chongqing, Peoples R China."

来源：FRONTIERS IN ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000894622700001

JCR分区：Q2

影响因子：4.7

年份：2022

卷号：12

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：sarcopenia; body composition; liver growth; portal vein embolization; ALPPS; liver cancer

摘要："Purpose: The impact of sarcopenia on the future liver remnant (FLR) growth after portal vein occlusion, including portal vein embolization (PVE) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has gained increasing interest. This systematic review aimed to explore whether sarcopenia was associated with insufficient FLR growth after PVE/ALPPS stage-1. Methods: A systematic literature search was performed in PubMed, Embase, Web of Science, and Cochrane Library up to 05 July 2022. Studies evaluating the influence of sarcopenia on FLR growth after PVE/ALPPS stage-1 in patients with liver cancer were included. A predefined table was used to extract information including the study and patient characteristics, sarcopenia measurement, FLR growth, post-treatment complications and post-hepatectomy liver failure, resection rate. Research quality was evaluated by the Newcastle-Ottawa Scale. Results: Five studies consisting of 609 patients were included in this study, with a sample size ranging from 42 to 306 (median: 90) patients. Only one study was multicenter research. The incidence of sarcopenia differed from 40% to 67% (median: 63%). Skeletal muscle index based on pretreatment computed tomography was the commonly used parameter for sarcopenia evaluation. All included studies showed that sarcopenia impaired the FLR growth after PVE/ALPPS stage-1. However, the association between sarcopenia and post-treatment complications, post-hepatectomy liver failure, and resection rate remains unclear. All studies showed moderate-to-high quality. Conclusions: Sarcopenia seems to be prevalent in patients undergoing PVE/ALPPS and may be a risk factor for impaired liver growth after PVE/ALPPS stage-1 according to currently limited evidence."

基金机构：Medical Diagnostics Karolinska; [929646]

基金资助正文：Funding This research was funded by Medical Diagnostics Karolinska (grant number: 929646).